Autopsy report · NCT04438850

COVidIVERmectin: Ivermectin for Treatment of Covid-19

“Incidence has dramatically dropped and there is lack of eligible patients”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 10 months before it stopped.
• 93 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

IRCCS Sacro Cuore Don Calabria di Negrar

Sponsor type

University, hospital or other

Conditions

Covid19

Interventions

Ivermectin; Placebo

Participants

93

Sites

5

Countries

Italy

Trials that died the same way

• The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Heart Failure-Pilot Study
  “Lack of eligible patients” (74% match in meaning)
• Endothelial Protection in Convalescent COVID-19 Patients
  “Lack of the eligible patients” (74% match in meaning)
• Non-alcoholic Fatty Liver Disease (NAFLD) in HIV: The Role of Nutritional Interventions
  “Not enough eligible patients available” (70% match in meaning)
• Proof-of-concept Study of NSAID Hydrogel Patch in Treatment of Acute Pain
  “Due to lack of patients number” (70% match in meaning)
• Efficacy of Botulinum Toxin Versus Lidocaine in Treating Masticatory Myofascial Face Pain Using Ultrasound and EMG Guided Techniques
  “Lack of eligible patients willing and able to participate” (67% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.